Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract

American Journal of Reproductive Immunology

Volumn 56, Issue 5-6, 2006, Pages 356-363

  Keller, Marla J ^a   Herold, Betsy C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Genital herpes; Human immunodeficiency virus; Microbicides; Mucosal immunity

Indexed keywords

ACIDFORM; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BUFFER; BUFFER GEL; C 31G; CARRAGEENAN; CELLULOSE SULFATE; DETERGENT; DODECYL SULFATE SODIUM; MICROBICIDE; N 9; PLACEBO; POLYSACCHARIDE SULFATE; PRO 2000; RNA DIRECTED DNA POLYMERASE INHIBITOR; SURFACTANT; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

ARTICLE; ASSAY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE GENITAL SYSTEM; GENITAL HERPES; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE;

ANIMALS; ANTI-INFECTIVE AGENTS; FEMALE; GENITAL DISEASES, FEMALE; GENITALIA, FEMALE; HUMANS; IMMUNITY, MUCOSAL; SEXUALLY TRANSMITTED DISEASES;

EID: 33750541721     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2006.00436.x     Document Type: Article

References (60)

1. LaArence, J: Update: a 25th anniversary and a UN global AIDS summit. AIDS Read 2006; 16: 331-332.
2. Mbopi-Keou FX, Gresenguet G, Mayaud P, Weiss HA, Gopal R, Matta M, Paul JL, Brown DW, Hayes RJ, Mabey DC, Belec L: Interactions between herpes simplex virus type 2 and human immunodeficiency virus type 1 infection in African women: Opportunities for intervention. J Infect Dis 2000; 182: 1090-1096.
3. Warren T, Ebel C: Counseling the patient who has genital herpes or genital human papillomavirus infection. Infect Dis Clin North Am 2005; 19: 459-476.
4. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ: Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20: 73-83.
5. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC: Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357: 1149-1153.
6. Mertz GJ, Rosenthal SL, Stanberry LR: Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes ? Sex Transm Dis 2003; 30: 801-802.
7. Haddow LJ, Dave B, Mindel A, McPhie KA, Chung C, Marks C, Dwyer DE: Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex Transm Infect 2006; 82: 255-259.
8. Ribes JA, Steele AD, Seabolt JP, Baker DJ: Six-year study of the incidence of herpes in genital and nongenital cultures in a central Kentucky medical center patient population. J Clin Microbiol 2001; 39: 3321-3325.
9. Lowhagen GB, Tunback P, Andersson K, Bergstrom T, Johannisson G: First episodes of genital herpes in a Swedish STD population: A study of epidemiology and transmission by the use of herpes simplex virus (HSV) typing and specific serology. Sex Transm Infect 2000; 76: 179-182.
10. Roberts CM, Pfister JR, Spear SJ: Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis 2003; 30: 797-800.
11. Kim HN, Meier A, Huang ML, Kuntz S, Selke S, Celum C, Corey L, Wald A: Oral herpes simplex virus type 2 reactivation in HIV-positive and -negative men. J Infect Dis 2006; 194: 420-427.
12. van de Wijgert J, Jones H: Challenges in microbicide trial design and implementation. Stud Fam Plann 2006; 37: 123-129.
13. Hillier SL, Moench T, Shattock R, Black R, Reichelderfer P, Veronese F: In vitro and in vivo: The story of nonoxynol 9. J Acquir Immune Defic Syndr 2005; 39: 1-8.
14. Howett MK, Neely EB, Christensen ND, Wigdahl B, Krebs FC, Malamud D, Patrick SD, Pickel MD, Welsh PA, Reed CA, Ward MG, Budgeon LR, Kreider JW: A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother 1999; 43: 314-321.
15. Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR: Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 2001; 28: 417-423.
16. Amaral E, Faundes A, Zaneveld L, Waller D, Garg S: Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception 1999; 60: 361-366.
17. Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, Waller DP, Anderson RA, Profy AT, Klotman ME, Keller MJ, Herold BC: Acidform inactivates herpes simplex virus and prevents genital herpes in a mouse model: Optimal candidate for microbicide combinations. J Infect Dis 2006; 194: 795-803.
18. Scordi-Bello IA, Mosoian A, He C, Chen Y, Cheng Y, Jarvis GA, Keller MJ, Hogarty K, Waller DP, Profy AT, Herold BC, Klotman ME: Candidate sulfonated and sulfated topical microbicides: Comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49: 3607-3615.
19. Pearce-Pratt R, Phillips DM: Sulfated polysaccharides inhibit lymphocyte-to-epithelial transmission of human immunodeficiency virus-1. Biol Reprod 1996; 54: 173-182.
20. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC: Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 2004; 48: 2025-2036.
21. Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S: Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses. Antiviral Res 2005; 68: 139-146.
22. Moore JP, Shattock RJ: Preventing HIV-1 sexual transmission -not sexy enough science, or no benefit to the bottom line ? J Antimicrob Chemother 2003; 52: 890-892.
23. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, Masse B, Eshleman SH, Hendrix C, Morrow K, Rooney JF, Soto-Torres L: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20: 543-551.
24. De Pasquale MP, Leigh Brown AJ, Uvin SC, Allega-Ingersoll J, Caliendo AM, Sutton L, Donahue S, D'Aquila RT: Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 37-44.
25. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA: HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006; 20: F9-F13.
26. Herold BC, Kirkpatrick R, Marcellino D, Travelstead A, Pilipenko V, Krasa N, Bremer J, Dong LJ, Cooper MD: Bile salts: natural detergents for the prevention of sexually transmitted diseases. Antimicrob Agents Chemother 1999; 43: 745-751.
27. Krebs FC, Miller SR, Catalone BJ, Welsh PA, Malamud D, Howett MK, Wigdahl B: Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: Comparative sensitivity of primary human vaginal keratinocytes. Antimicrob Agents Chemother 2000; 44: 1954-1960.
28. Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod 2004; 71: 761-769.
29. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiegne-Traore V, Uaheowitchai C, Karim SS, Masse B, Perrins J, Laga M: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002; 360: 971-977.
30. Roddy RE, Cordero M, Cordero C, Fortney JA: A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS 1993; 4: 165-170.
31. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J, Kitchen VS: Safety study of nonoxynol-9 as a vaginal microbicide: Evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17: 327-331.
32. Marrazzo JM, Wiesenfeld HC, Murray PJ, Busse B, Meyn L, Krohn M, Hillier SL: Risk factors for cervicitis among women with bacterial vaginosis. J Infect Dis 2006; 193: 617-624.
33. John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC: Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192: 1731-1740.
34. Hazrati, Galen B, Lu W, Wang W, Ouyany Y, Keller MJ, Lehrer RI, Herold BC: Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; (in press).
35. Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, Lal RB, Lehrer RI: Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173: 515-520.
36. Wu Z, Cocchi F, Gentles D, Ericksen B, Lubkowski J, Devico A, Lehrer RI, Lu W: Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro. FEBS Lett 2005; 579: 162-166.
37. Chang TL, Vargas J, Jr, DelPortillo A, Klotman ME: Dual role of alpha-defensin-1 in anti-HIV-1 innate immunity. J Clin Invest 2005; 115: 765-773.
38. Feng Z, Hubyak GR, Lederman MM, Weinberg A: Cutting edge: human beta defensin 3 - a novel antagonist of the HIV-1 coreceptor CXCR4. J Immunol 2006; 177: 782-786.
39. Sun L, Finnegan CM, Kish-Catalone T, Blumenthal R, Garzino-Demo P, La Terra Maggiore GM, Berrone S, Kleinman C, Wu Z,
40. Abdelwahab S, Lu W, Garzino-Demo A: Human beta-defensins suppress human immunodeficiency virus infection: Potential role in mucosal protection. J Virol 2005; 79: 14318-14329.
41. Quinones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A: Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17: F39-F48.
42. Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT: Human alpha-defensins block papillomavirus infection. Proc Natl Acad Sci U S A 2006; 103: 1516-1521.
43. Braida L, Boniotto M, Pontillo A, Tovo PA, Amoroso A, Crovella S: A single-nucleotide polymorphism in the human beta-defensin 1 gene is associated with HIV-1 infection in Italian children. AIDS 2004; 18: 1598-1600.
44. Aldred PM, Hollox EJ, Armour JA: Copy number polymorphism and expression level variation of the human alpha-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005; 14: 2045-2052.
45. McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM: Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456-464.
46. Pillay K, Coutsoudis A, Agadzi-Naqvi AK, Kuhn L, Coovadia HM, Janoff EN: Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183: 653-656.
47. Farquhar C, VanCott TC, Mbori-Ngacha DA, Horani L, Bosire RK, Kreiss JK, Richardson BA, John-Stewart GC: Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J Infect Dis 2002; 186: 1173-1176.
48. Fakioglu E, Fam E, Herold BC: HSV downregulates secretory leukocyte protease inhibitor (SLPI), a major component of mucosal immunity: A novel immune evasion strategy may facilitate HIV co-infection. 2006 Pediatric Academic Societies' Annual Meeting, San Francisco, CA, 2006.
49. Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP: Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183: 1243-1248.
50. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ: Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 2006; 3: 1-12.
51. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC: PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: A double-blind placebo-controlled trial. J Infect Dis 2006; 193: 27-35.
52. Schwartz JL, Mauck C, Lai JJ, Creinin MD, Brache V, Ballagh SA, Weiner DH, Hillier SL, Fichorova RN, Callahan M: Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: A randomized double-blind Phase I safety study. Contraception 2006; 74: 133-140.
53. Humphreys TL, Schnizlein-Bick CT, Katz BP, Baldridge LA, Hood AF, Hromas RA, Spinola SM: Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition. J Immunol 2002; 169: 6316-6323.
54. Kinter A, Catanzaro A, Monaco J, Ruiz M, Justement J, Moir S, Arthos J, Oliva A, Ehler L, Mizell S, Jackson R, Ostrowski M, Hoxie J, Offord R, Fauci AS: CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction. Proc Natl Acad Sci U S A 1998; 95: 11880-11885.
55. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175: 7560-7567.
56. Valore EV, Park CH, Igreti SL, Ganz T: Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187: 561-568.
57. Galen B, Martin A, Garin A, Kasowitz A, Lira SA, Keller M, Herold BC: Impact of microbicides on mucosal immunity in the genital tract; murine model to predict safety. Microbicides 2006, Cape Town, South Africa, 2006.
58. Cone RA, Hoen T, Wong X, Abusuwwa R, Anderson DJ, Moench TR: Vaginal microbicides: Detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis 2006; 6: 90-105.
59. Peretti S, Shaw A, Blanchard J, Bohm R, Morrow G, Lifson JD, Gettie A, Pope M: Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses. Blood 2005; 106: 1305-1313.
60. MasCasullo V, Fam E, Keller MJ, Herold BC: Role of mucosal immunity in preventing genital herpes infection. Viral Immunol 2005; 18: 595-606.